The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
 
 
Employment - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Single agent ONC201 in adult recurrent H3 K27M-mutant glioma.
 
Isabel Arrillaga
Honoraria - Merck
Consulting or Advisory Role - Agios; Insys Therapeutics; Karus Therapeutics
 
Sylvia Kurz
No Relationships to Disclose
 
Ashley Sumrall
No Relationships to Disclose
 
Nicholas A. Butowski
Honoraria - Vascular Biogenics; Vascular Biogenics
Consulting or Advisory Role - Abbvie; Genentech/Roche; Medicenna; Omniox
Speakers' Bureau - Genentech/Roche
Research Funding - Abbvie; Bristol-Myers Squibb; Five Prime Therapeutics; Lilly; Medicenna; Merck; Merrimack; Tocagen
 
Rebecca A. Harrison
No Relationships to Disclose
 
John Frederick De Groot
Employment - Helsinn Therapeutics (I); ZIOPHARM Oncology (I)
Leadership - ZIOPHARM Oncology (I)
Stock and Other Ownership Interests - Gilead Sciences; ZIOPHARM Oncology (I)
Consulting or Advisory Role - Abbvie; Agios; AstraZeneca; Blue Earth Diagnostics; Boston Biomedical; CarThera; Deciphera; Five Prime Therapeutics; Foundation Medicine; Genentech/Roche; GenomiCare; GW Pharmaceuticals; Insys Therapeutics; Kadmon; Kairos Ventures; KIYATEC; Merck; Mundipharma Research; Novogen; Vascular Biogenics
Research Funding - Deciphera; EMD Serono; Lilly; Mundipharma; Novartis; Sanofi
Patents, Royalties, Other Intellectual Property - AstraZeneca - Research Support; Deciphera Pharmaceuticals - Research Support; Eli Lilly - Research Support; EMD-Serono - Research Support; Novartis - Research Support; Sanofi-Aventis - Research Support
Travel, Accommodations, Expenses - Blue Earth Diagnostics
 
Nicole A. Shonka
No Relationships to Disclose
 
Frank S. Lieberman
No Relationships to Disclose
 
Yazmin Odia
No Relationships to Disclose
 
Rohinton Tarapore
No Relationships to Disclose
 
Krystal Merdinger
Employment - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
Joshua E. Allen
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
Patents, Royalties, Other Intellectual Property - Oncoceutics
 
Wolfgang Oster
Employment - Oncoceutics
Leadership - Oncoceutics
Stock and Other Ownership Interests - Oncoceutics
 
Minesh P. Mehta
Leadership - Oncoceutics
Consulting or Advisory Role - Abbvie; AstraZeneca; Blue Earth Diagnostics; Celgene; Tocagen; Varian Medical Systems
Research Funding - Novocure (Inst)
Patents, Royalties, Other Intellectual Property - WARF patent 14/934,27, TOPICAL VASOCONSTRITOR PREPARATIONS AND METHODS FOR PROTECTING CELLS DURING CANCER CHEMOTHERAPY AND RADIOTHERAPY
 
Timothy Francis Cloughesy
Stock and Other Ownership Interests - Notable Labs
Consulting or Advisory Role - Abbvie; Agios; Alexion Pharmaceuticals; Boehringer Ingelheim; Boston Biomedical; Bristol-Myers Squibb; Celgene; cortice; Deciphera; Genocea Biosciences; GW Pharmaceuticals; Human Longevity, Inc; Insys Therapeutics; KIYATEC; Lilly; Merck; NewGen Therapeutics; Notable Labs; Novartis; Novocure; Novogen; Oxigene; Pfizer; Puma Biotechnology; Roche/Genentech; Sunovion; Tocagen; VBI Vaccines; VBL Therapeutics; wellcome trust
Other Relationship - Global Coalition for Adaptive Research
 
Andrew S. Chi
Employment - Neon Therapeutics
Consulting or Advisory Role - Cota Healthcare
Patents, Royalties, Other Intellectual Property - Fused Bicyclic Heterocycles as Therapeutic Agents (Inventor) Provisional Patent Application No. 62/742,041 filed on October 5, 2018
Travel, Accommodations, Expenses - Abbvie
 
Andrew B. Lassman
Honoraria - Abbvie; WebMD
Consulting or Advisory Role - Abbvie; Agios; BioClinica; Celgene; Cortice; Kadmon; Karyopharm Therapeutics; Northwest Biotherapeutics; Orbus Therapeutics; Sapience Therapeutics
Research Funding - Abbvie (Inst); Aeterna Zentaris (Inst); Amgen (Inst); BeiGene (Inst); Celldex (Inst); Genentech/Roche (Inst); Kadmon (Inst); Karyopharm Therapeutics (Inst); Millennium (Inst); Novartis (Inst); Oncoceutics (Inst); Pfizer (Inst); VBI Vaccines (Inst)
Travel, Accommodations, Expenses - Agios; Karyopharm Therapeutics; Novocure
 
Tracy Batchelor
Honoraria - Champions Biotechnology; Genomicare; Imedex; Merck; NXDC; UpToDate
Consulting or Advisory Role - Amgen; GenomiCare; Merck; NXDC
Travel, Accommodations, Expenses - Genomicare; Merck; Roche/Genentech
 
Patrick Y. Wen
Consulting or Advisory Role - AbbVie; Agios; AstraZeneca; Deciphera; Genentech/Roche; GW Pharmaceuticals; Immunomic Therapeutics; KIYATEC; Lilly; Puma Biotechnology; Taiho Pharmaceutical; Tocagen; Vascular Biogenics; VBI Vaccines; ZIOPHARM Oncology
Speakers' Bureau - Merck; Prime Oncology
Research Funding - Abbvie (Inst); Agios (Inst); AstraZeneca (Inst); AstraZeneca (Inst); Beigene (Inst); Genentech/Roche (Inst); Kazia Therapeutics (Inst); Lilly (Inst); MediciNova (Inst); Merck (Inst); Novartis (Inst); Oncoceutics (Inst); Vascular Biogenics (Inst); Vascular Biogenics (Inst); VBI Vaccines (Inst)